Open Access<p>Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial</p>
Author(s) -
Afisi S Ismaila,
Nancy Risebrough,
Melanie Schroeder,
Dhvani Shah,
Antonio Jiménez Martín,
Emma C. Goodall,
Kerigo Ndirangu,
Gerard J. Criner,
Mark T. Dransfield,
David Halpin,
MeiLan K. Han,
David A. Lomas
Publication year - 2019
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s216072
Subject(s) - medicine , copd , fluticasone propionate , cost effectiveness , quality adjusted life year , discontinuation , exacerbation , confidence interval , asthma , risk analysis (engineering)
We assessed the cost-effectiveness of single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus FF/VI or UMEC/VI from a Canadian public healthcare perspective, incorporating data from the IMPACT trial in chronic obstructive pulmonary disease (COPD) (NCT02164513).